Noxopharm Ltd. (AU:NOX) has released an update.
Noxopharm Limited is set to start a groundbreaking first-in-human clinical trial in early 2025 for its novel drug candidate, SOF-SKN™, targeting the autoimmune disease cutaneous lupus erythematosus (CLE). The trial, named HERACLES, aims to not only alleviate symptoms but also treat the underlying causes of CLE, with potential expansion into broader autoimmune markets. The company’s swift progress to the clinical trial stage underscores its commitment to leveraging the Sofra™ platform’s potential to address a significant unmet medical need in autoimmune diseases.
For further insights into AU:NOX stock, check out TipRanks’ Stock Analysis page.
